[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-related-cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-related-cognitive-impairment":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,71,103,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639303","the-computerized-retraining-and-functional-treatment---group-intervention-100639303",false,"NCT07591857","The Computerized Retraining and Functional Treatment - Group Intervention","The Computerized Retraining and Functional Treatment: Effectiveness-implementation Hybrid Trial of Group Teleintervention Among Breast Cancer Survivors With Cognitive Impairment","CRAFT-G","Inclusion Criteria:\n\n1. women, 18 years old and older\n2. A subjective concern about declines in cognitive functioning related to a diagnosis of breast cancer and\u002For cancer related treatment\n3. Objective cognitive decline with no dementia (19\\\u003CMOCA)\n4. 6 months or more after completion of an active treatment for cancer\n5. Daily access to the internet and sufficient basic skills to operate a computer\n\nExclusion Criteria:\n\n* Unstable psychiatric or other health condition according to participants' self-report and medical file.","FEMALE","18 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to examine the efficacy of a novel, remotely-applied group intervention, Cognitive Retraining and Functional Treatment Group (CRAFT-G), designed to improve cognitive function, mental health and functional outcome in breast cancer survivors (BCS) with Cancer-Related Cognitive Impairment (CRCI) while simultaneously collecting data on the barriers and facilitators of implementation in clinical settings. The main question it aims to answer is:\n\nWe hypothesize that participants receiving CRAFT-G will show gains in mental health, cognitive and daily function, and that the CRAFT-G benefits will endure for three months following treatment completion.\n\nParticipants assigned to the waitlist control will crossover to the CRAFT-G intervention group after 6 weeks.\n\nParticipants will ask to complete CRAFT-G intervention, which include:\n\n* Six remote group sessions (1.5hr each)\n* Between the sessions, participants will be guided to complete CRCI-specific computerized cognitive training (CCT) 3 times per week delivered using dedicated app.\n* Psychoeducation materials Assessment will take place in 3 time points: before intervention (frontal meeting for baseline assessment), post intervetion and 3 months post intervention.\n\nThe study will be conducted to explore implementation barriers and facilitators. This will be done by endline qualitative interviews with the participants' research group.",[27,28],"Cancer Related Cognitive Impairment","Breast Cancer Survivor",[30,31,32],"Tele-rehabilitation","Cognitive training","Group therapy","RECRUITING","2026-05-11",{"date":36,"type":37},"2026-05-18","ACTUAL",{"date":39,"type":37},"2025-11-16",{"date":41,"type":21},"2028-06",{"name":43,"class":44},"Hadassah Medical Organization","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100640750","cognitive-impairment-assessment-in-breast-cancer-survivors-100640750","NCT07582770","Cognitive Impairment Assessment in Breast Cancer Survivors","Validation of Neuropsychological Tests for the Assessment of Cognitive Impairment in Breast Cancer Survivors","Inclusion Criteria:\n\n* Age between 18 and 65 years old\n* Patient with a previous documented diagnosis of non-metastatic breast cancer (only for breast cancer survivor gruop)\n* Patient has completed chemotherapy for at least 6 months and for a maximum of 36 months if planned (only for breast cancer survivor gruop)\n* Understanding of the Italian language and ability to give informed consent\n\nExclusion Criteria:\n\n* Presence of brain metastases or history of brain radiation therapy (only for breast cancer survivor gruop)\n* Patient with previous diagnosis of other malignant tumors in addition to breast cancer (only for breast cancer survivor gruop)\n* Patient with a previous diagnosis of malignant carcinomas (only for control gruop)\n* Patient with a history of brain damage with unresolved neurological consequences\n* Patient with previous or current serious neurological pathologies\n* Patient with severe psychiatric conditions\n* Patient with systemic pathologies that could interfere with cognitive abilities\n* Patient taking medications that have a strong cognitive impact and that have not been stabilized for at least 4 weeks prior to enrollment\n* Patient with visual or hearing impairments that are not properly corrected\n* Patient with any disability that might compromise the validity of cognitive tests",true,"65 Years",{"count":56,"type":21},200,"OBSERVATIONAL","This study is a monocentric, observational, cross-sectional study with a case-control design, aimed at evaluating the construct validity, discriminative ability, and diagnostic accuracy of a second-level neuropsychological test battery for the detection of cancer-related cognitive impairment in breast cancer survivors.",[27,60],"Breast Cancer Survivors","NOT_YET_RECRUITING","2026-05-06",{"date":64,"type":37},"2026-05-13",{"date":66,"type":21},"2026-05",{"date":68,"type":21},"2030-04",{"name":70,"class":44},"European Institute of Oncology",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":45},"100640125","phase-3-electroacupuncture-for-cognitive-toxicity-in-cancer-survivors-assessing-implementation-cost-and-effectiveness-for-integration-100640125","NCT07583979","Electroacupuncture for Cognitive Toxicity in Cancer Survivors: Assessing Implementation, Cost, and Effectiveness for Integration","ElectroAcupuncture to Manage Symptoms of Cognitive Toxicity in Cancer Survivors: Assessing impLementation, Cost, and effectIveness for inteGratioN (EAST-ALIGN)","EAST-ALIGN","Inclusion Criteria:\n\nSurvivor participants\n\n* Aged 21-85 years\n* Documented cancer diagnosis in electronic health records\n* Perceived by the survivor or oncology care provider that cognitive function has worsened since cancer diagnosis and\u002For beginning of cancer treatment\n* Able to understand English or Mandarin\n* Able to provide informed consent\n\nStakeholder participants\n\n* Aged ≥21 years\n* Identified as having a relevant role, experience, or perspective relating to the delivery, referral, coordination, or implementation of EA or supportive cancer care in the study context\n* Able to provide informed consent\n\nExclusion Criteria:\n\nSurvivor participants\n\n* Presence of brain metastases\n* Severe needle phobia\n* Known bleeding disorder (e.g. hemophilia, von Willebrand disease, thrombocytopenia).\n* Current use of antiplatelet or anticoagulant therapy (e.g. aspirin, clopidogrel, warfarin, enoxaparin, rivaroxaban, dabigatran)\n* Known blood-borne communicable disease (e.g. hepatitis B, hepatitis C, human immunodeficiency virus)\n* Presence of a pacemaker or other electronic implant, or a history of epilepsy\n* Current acupuncture treatment or acupuncture received within the past 3 months\n* Current pregnancy, planned pregnancy over the next 5 months, or breastfeeding.\n* Incapable of providing informed consent\n* Unable to complete study procedures\n\nStakeholder participants\n\n* Incapable of providing informed consent\n* Unable to complete study procedures","ALL","21 Years","85 Years",{"count":83,"type":21},168,[85],"PHASE3","The goal of this clinical trial is to evaluate the clinical effectiveness and understand the biological mechanisms of electroacupuncture (EA) in reducing cognitive toxicity among cancer survivors. The study aims are:\n\n* To evaluate the clinical effectiveness of a 10-week EA regimen targeting neuropsychiatric-related acupoints in reducing cognitive toxicity among cancer survivors in Singapore.\n* To explore the biological mechanisms underlying EA's effects on cognitive function.\n* To assess the early implementation of EA for managing cognitive toxicity in cancer survivors.\n\nResearchers will compare results from the true EA arm, sham EA arm and waitlist control arm, to see if electroacupuncture can help improve cognitive issues related to cancer and its treatment, how it may work, and what factors may affect how it is delivered in cancer care.\n\nParticipants will:\n\n* Be assigned to either of the 3 arms (true EA, sham EA, waitlist control)\n* Received 10 EA sessions (if assigned to true or sham EA arm)\n* Complete 3 study assessment visits at baseline, Week 13, and Week 17\n* Be invited to a one-time interview to share their study experience (optional, if selected)",[88],"Cancer-related Cognitive Impairment",[90,91,92,88,93,94,95],"Electroacupuncture","Acupuncture","Traditional Chinese Medicine","Cognitive Toxicity","Oncology","Survivor",{"date":64,"type":37},{"date":98,"type":21},"2026-07-01",{"date":100,"type":21},"2029-01-13",{"name":102,"class":44},"National Cancer Centre, Singapore",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":79,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100505004","photobiomodulation-for-cancer-related-cognitive-impairment-100505004","NCT05855694","Photobiomodulation for Cancer-Related Cognitive Impairment","Pilot Study of Photobiomodulation for Cancer-Related Cognitive Impairment","Inclusion Criteria:\n\n* Adults ≥ 18 years\n* Previous diagnosis of stage I-III non-central nervous system solid tumor malignancy, Hodgkin, or Non-Hodgkin lymphoma\n* Completed cancer treatment (chemotherapy and\u002For radiation) more than 6 months ago but less than 5 years ago (Current concurrent endocrine therapy, anti-HER-2 therapy allowed, or other stable maintenance therapies (such as rituximab) will be allowed.\n* Self-reported cognitive complaints (score ≤ 54 on the Functional Assessment of Cancer Therapy-Cognition, Version 3, Perceived Cognitive Impairment subscale)\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n* Ability to read, write and understand either English OR Spanish.\n\nExclusion Criteria:\n\n* Current pregnancy or nursing status\n* Current use of Photobiomodulation (PBM) (for any reason)\n* A lifetime history of any brain tumor or central nervous system metastasis\n* Previous use of intrathecal chemotherapy, chimeric antigen receptor treatment (CAR-T), or stem cell\u002Fmarrow transplant\n* Known history of other neurological conditions involving impaired cognitive function (such as Alzheimer's Disease and related dementias, Parkinson's Disease, or Multiple Sclerosis).",{"count":111,"type":21},30,[24],"This is a single site, pilot randomized, double blinded control trial designed to assess changes in cognitive symptoms in cancer survivors with cancer-related cognitive impairment. Patients will be randomized into one of two Arms: Intervention or Control.\n\n* Arm A: Intervention Group: Use of the THOR LED Photobiomodulation helmet 3x per week for 6 weeks. Helmet will be in 'therapeutic setting', 35mW\u002Fcm2 = 42J\u002Fcm2\n* Arm B: Control Group: Use of the THOR LED Photobiomodulation helmet 3x per week for 6 weeks. Helmet will be in 'placebo setting', 0mW\u002Fcm2 = 0J\u002Fcm2\n\nThis study has been designed to assess the hypothesis that Photobiomodulation can have a positive impact on cognitive symptoms in cancer survivors with cancer-related cognitive impairment.\n\n30 participants will be recruited for this study, 15 per group. Self-report questionnaires assessing cognitive concerns, cognitive abilities, quality of life, depression, and anxiety will be administered at three timepoints through the study Baseline, End of Study Visit and 1 Month Follow Up",[88],[116],"Cancer Survivor","2026-05-01",{"date":62,"type":37},{"date":120,"type":21},"2026-06",{"date":122,"type":21},"2029-06",{"name":124,"class":44},"Arash Asher, MD",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":53,"sex":79,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100570699","effects-of-cognitive-training-on-chemotherapy-induced-cognitive-impairment-in-colon-cancer-patients-undergoing-treatmentchemobrain-in-oncology-patients-with-colon-cancer-undergoing-active-treatment-100570699","NCT06710639","Effects of Cognitive Training on Chemotherapy-Induced Cognitive Impairment in Colon Cancer Patients Undergoing Treatment(Chemobrain) in Oncology Patients With Colon Cancer Undergoing Active Treatment","Effects of a Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Oncology Patients With Colon Cancer Undergoing Active Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\nBeing an adult (18 years or older). Having a recent pathological diagnosis of newly diagnosed colon cancer and starting oncological treatment.\n\nBeing fully capable of performing daily functions. Willingness to voluntarily participate in the study and signing the informed consent.\n\nExclusion Criteria:\n\nLack of literacy skills or significant language comprehension deficits. Having a diagnosis of a Central Nervous System tumor or participating in another cognitive stimulation program.\n\nHaving a clinical diagnosis of a neurocognitive disorder as defined in the DSM-V.\n\nWithdrawal Criteria:\n\nDropping out of the program or not completing the final evaluation.",{"count":133,"type":21},50,[24],"Introduction: With the increasing survival rate in colon cancer, as a result of technological and biomedical advancements, it is essential to thoroughly study the secondary symptoms related to the oncological disease process. One of the most common and underestimated symptoms is cancer-related cognitive impairment (CRCI).\n\nObjective: To evaluate the efficacy of a cognitive training program in controlling CRCI in individuals with colon cancer undergoing active treatment.\n\nMethodology: A randomized controlled clinical trial with two parallel groups: an intervention group (IG) and a control group (CG). The study population will include individuals newly diagnosed with colon cancer. A sample size of 50 participants has been estimated, with 25 in each group, to detect a difference of 2.95 points or more in the MoCA cognitive impairment questionnaire. All participants will receive an educational leaflet based on the new WHO guidelines, which recommend specific measures to reduce the risk of cognitive impairment. In addition to receiving this informational leaflet, the IG will participate in a cognitive training program (CT) focused on everyday cognition (EC) individually. Each participant will receive a dossier with 80 intervention sessions divided into four training periods (P1-P4), each containing 20 activities. Each period will last for one month. Baseline and 4-month post-intervention evaluations will be conducted for both groups, measuring sociodemographic and clinical variables, as well as study-related cognitive impairment variables: Cognitive function (MoCA test), Everyday Cognition (PECC), Anxiety (Hamilton), Functionality (LB), Sleep Quality (PSQI), Quality of Life (ECOG), and Subjective Memory Complaints (FACT-COG).\n\nImpact: The results of this study could lead to the design of specific cognitive interventions and the establishment of protocols for colon cancer patients undergoing active treatment, helping them manage one of the most underestimated symptoms in this patient population-CRCI-whose incidence is increasing due to the improved survival rates in this disease.",[94,88,137,138,139,140],"Cognitive Training","Everyday Cognition","Clinical Trials","Colon Cancer",[94,142,31,143,144,145],"Cancer-related cognitive impairment","Everyday cognition","Clinical trials","Colon cancer","2024-11-26",{"date":148,"type":37},"2024-11-29",{"date":150,"type":21},"2025-03-01",{"date":152,"type":21},"2026-01-31",{"name":154,"class":44},"University of Salamanca"]